WATCH TIME: 3 minutes
Expanding knowledge on benefits of low sodium oxybates: Richard Bogan, MD, FCCP, FAASM
“I’m thinking about the fact that the FDA said this is a clinically superior drug. It’s a safer drug, it’s lower in sodium, and it’s still oxybate, the same group. Now we have clinical experience with the drug in terms of of the transition of patients from Xyrem to Xywav, the lower sodium group. For most people it’s gram-for-gram and quite easy for patients to understand.”
In July 2020, the FDA approved JZP-258 (Xywav; Jazz Pharmaceutical), an oral solution of calcium, magnesium, potassium and sodium oxybates, for the treatment of cataplexy or excessive daytime sleepiness (EDS) in patients 7 years of age or older. parent with narcolepsy. Just over a year later, the FDA approved an expanded indication of the drug for patients with idiopathic hypersomnia, becoming the first treatment approved for this indication.
Since its original approval, the drug has been used in numerous analyzes further demonstrating its efficacy and safety in both populations, including some presented at this year’s 2022 annual SLEEP meeting, June 4-8, in Charlotte, North. carolina. Richard Bogan, MD, FCCP, FAASM, was the principal investigator for the Phase 3 trial that led to the approval of JZP-258 in narcolepsy. He sat down with NeurologyLive at the meeting to discuss the benefits of low sodium oxybate and the improved general knowledge of the drug since it first came to market.